ETORICOXIB

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H15ClN2O2S
Molecular Weight	358.842
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=C(C=N1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O

InChI

InChIKey=MNJVRJDLRVPLFE-UHFFFAOYSA-N

InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3

HIDE SMILES / InChI

Molecular Formula	C18H15ClN2O2S
Molecular Weight	358.842
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Arcoxia_6_12/WC500012804.pdf

Etoricoxib is a selective COX-2 inhibitor, which is approved in Europe for the treatment of inflammatory disorders such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain conditions, gout and postoperative dental surgery pain.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostaglandin G/H synthase 2 51 Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Arcoxia_6_12/WC500012804.pdf	Inhibitor 8504		5.0 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Osteoarthritis 157 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Arcoxia_6_12/WC500012804.pdf	Palliative	Approved 8583	ARCOXIA Approved Use ARCOXIA is indicated in the symptomatic relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and the pain and signs of inflammation associated with acute gouty arthritis. Launch Date 2004
Rheumatoid arthritis 320 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Arcoxia_6_12/WC500012804.pdf	Palliative	Approved 8583	ARCOXIA Approved Use ARCOXIA is indicated in the symptomatic relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and the pain and signs of inflammation associated with acute gouty arthritis. Launch Date 2004
Acute gouty arthritis 2 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Arcoxia_6_12/WC500012804.pdf	Palliative	Approved 8583	ARCOXIA Approved Use ARCOXIA is indicated in the symptomatic relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and the pain and signs of inflammation associated with acute gouty arthritis. Launch Date 2004
Pain 619 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Arcoxia_6_12/WC500012804.pdf	Primary	Approved 8583	ARCOXIA Approved Use ARCOXIA is indicated in the symptomatic relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and the pain and signs of inflammation associated with acute gouty arthritis. Launch Date 2004
Ankylosing spondylitis 33 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Arcoxia_6_12/WC500012804.pdf	Palliative	Approved 8583	ARCOXIA Approved Use ARCOXIA is indicated in the symptomatic relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and the pain and signs of inflammation associated with acute gouty arthritis. Launch Date 2008
Postoperative dental surgery pain 2 Sources: https://www.medicines.org.uk/emc/PIL.29146.latest.pdf	Primary	Approved 8583	ARCOXIA Approved Use ARCOXIA is indicated in the symptomatic relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and the pain and signs of inflammation associated with acute gouty arthritis. Launch Date 2004

C_max

Value	Dose	Analyte	Population
95 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11583479/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
201 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11583479/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
411 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11583479/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
788 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11583479/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2186 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11583479/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.43 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.56 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
0.53 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.27 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.14 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4.37 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.05 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.59 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1752 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1698 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1917 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2209 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1694 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14517196/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1654 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14517196/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1680 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14517196/	60 mg 1 times / 2 days steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
1.55 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11583479/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.47 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11583479/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11583479/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
13.29 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11583479/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
40.56 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11583479/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
41.35 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
40.16 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
9.08 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
18.57 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
35.84 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
76.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
18.43 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
37.83 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
22.87 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
31.36 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
34.71 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
33.49 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
17.77 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14517196/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
20.66 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14517196/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
15.92 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14517196/	60 mg 1 times / 2 days steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
22.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11583479/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
22.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11583479/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
21.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11583479/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
22.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11583479/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
21.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11583479/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
28.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
27.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
28.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
29.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
28.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
27.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
23.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
25.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12638395/	120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
19.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
24.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
21.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
20.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
21.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14517196/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
24.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14517196/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
30.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14517196/	60 mg 1 times / 2 days steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Analyte	Population
12.4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12.6% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12.6% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14681341/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14517196/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ETORICOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14517196/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14517196/	60 mg 1 times / 2 days steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ETORICOXIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
120 mg 1 times / day steady-state, oral Recommended Dose: 120 mg, 1 times / day Route: oral Route: steady-state Dose: 120 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12638395/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/12638395/	Sources: https://pubmed.ncbi.nlm.nih.gov/12638395/
90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/	Disc. AE: Dyspepsia, Upper abdominal pain... AEs leading to discontinuation/dose reduction: Dyspepsia (1.4%) Upper abdominal pain (0.9%) Abdominal pain (0.7%) Hypertension (1.5%) Diarrhea (0.6%) Cerebral hemorrhage (grade 5, 0.03%) ALT increased AST increased Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/

AEs

AE	Significance	Dose	Population
Diarrhea	0.6% Disc. AE	90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/
Abdominal pain	0.7% Disc. AE	90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/
Upper abdominal pain	0.9% Disc. AE	90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/
Dyspepsia	1.4% Disc. AE	90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/
Hypertension	1.5% Disc. AE	90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/
ALT increased	Disc. AE	90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/
AST increased	Disc. AE	90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/
Cerebral hemorrhage	grade 5, 0.03% Disc. AE	90 mg 1 times / day multiple, oral Recommended Dose: 90 mg, 1 times / day Route: oral Route: multiple Dose: 90 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17304660/

PubMed

Title	Date	PubMed
Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection.	2006-01	16013036
Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis.	2005-11	15731291
An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices.	2005-09-15	16009523
The molecular basis for coxib inhibition of p38alpha MAP kinase.	2005-08-01	15990304
Relative thromboembolic risks associated with COX-2 inhibitors.	2005-06-16	15956235
Protective effects of etoricoxib, a selective inhibitor of cyclooxygenase-2, in experimental periodontitis in rats.	2005-06	15853965
The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.	2005-05	15974563
Association between health-related quality of life and clinical efficacy endpoints in rheumatoid arthritis patients after four weeks treatment with anti-inflammatory agents.	2005-05	15906586
Etoricoxib: a highly selective COX-2 inhibitor.	2005-05	15827069
Quantitation of itopride in human serum by high-performance liquid chromatography with fluorescence detection and its application to a bioequivalence study.	2005-04-25	15734161
Gateways to clinical trials.	2005-04-19	15834459
[COX-2 inhibitors--one step forward and two steps back].	2005-04-07	15815733
Gateways to clinical trials.	2005-04	15834452
Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial.	2005-04	15819283
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.	2005-04	15818702
Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.	2005-03	15494548
A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma.	2005-03	15473012
Validated liquid chromatographic ultraviolet method for the quantitation of Etoricoxib in human plasma using liquid-liquid extraction.	2005-02-25	15664353
Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins.	2005-01-07	15591227
The analgesic effect of etoricoxib relative to that of cetaminophen analgesics: a randomized, controlled single-dose study in acute dental impaction pain.	2005-01	15881486
Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.	2005	15987231
Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?	2005	15813652
Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.	2004-12	15701208
[Comparison of preemptive analgesia efficacy between etoricoxib and rofecoxib in ambulatory gynecological surgery].	2004-12	15663229
Isolation and structural characterization of the photolysis products of etoricoxib.	2004-12	15638077
Novel insights and therapeutical applications in the field of inhibitors of COX-2.	2004-12	15579005
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.	2004-12	15530895
Gateways to clinical trials.	2004-11	15632957
Gateways to clinical trials.	2004-10	15605126
The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.	2004-10	15342613
Gateways to clinical trials.	2004-09-07	15349141
Gateways to clinical trials.	2004-09	15538546
The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: a randomized, double-blind clinical trial.	2004-09	15333415
The second generation of COX-2 inhibitors: clinical pharmacological point of view.	2004-08	15279595
First and second generations of COX-2 selective inhibitors.	2004-08	15279593
Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.	2004-07	15335413
Etoricoxib.	2004-05	15319795
[Etoricoxib (Arcoxia)].	2004-05	15270001
Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study.	2004-05	15220011
Evaluation of quality of life following treatment with etoricoxib in patients with arthritis or low-back pain: an open label, uncontrolled pilot study in Mexico.	2004-05	15140335
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.	2004-05	15117884
A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model.	2004-04-22	15100590
[Pharmacology and classification of cyclooxygenase inhibitors].	2004-04	15366670
Cyclooxygenase-2 inhibitors: do they have a role in emergency department prescribing?	2004-02	15239758
Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.	2004-01	14996519
[Rapidly acting and powerful antirheumatic drug now also approved in Germany. Arcoxia (etoricoxib, MSD)]].	2004	15675401
Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial.	2004	15370723
Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.	2004	15244490
A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy.	2004	15141994
Selective cyclooxygenase-2 inhibitors: similarities and differences.	2004	15124935

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is 30 mg once a day (osteoarthritis) and 60 mg once a day (rheumatoid arthritis, ankylosing spondylitis); the dose may be increased to a maximum of 60 mg (osteoarthritis) or 90 mg (rheumatoid arthritis, ankylosing spondylitis) once a day if needed. In case of acute pain conditions etoricoxib should be used only for the acute painful period. In gout the recommended dose is 120 mg once a day which should only be used for the acute painful period, limited to a maximum of 8 days. For the treatment of postoperative dental surgery pain the recommended dose is 90 mg once daily, limited to a maximum of 3 days treatment.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:09:13 GMT 2025` Edited by `admin` on `Mon Mar 31 18:09:13 GMT 2025`
Record UNII	WRX4NFY03R
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ARCOXIA

Preferred Name

English

ETORICOXIB

Official Name

English

MK-0663

Code

English

ETORICOXIB [MI]

Common Name

English

5-CHLORO-6'-METHYL-3-(4-(METHYLSULFONYL)PHENYL)-2,3'-BIPYRIDINE

Systematic Name

English

ETORICOXIB [USAN]

Common Name

English

L-791456

Code

English

Etoricoxib [WHO-DD]

Common Name

English

ETORICOXIB [MART.]

Common Name

English

2,3'-BIPYRIDINE, 5-CHLORO-6'-METHYL-3-(4-(METHYLSULFONYL)PHENYL)-

Systematic Name

English

etoricoxib [INN]

Common Name

English

Classification Tree Code System Code

WHO-ATC

M01AH05